HF
CURX

HRT Financial’s Curanex Pharmaceuticals CURX Stock Holding History

HRT Financial’s Portfolio CURX Stock Details CURX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-12,378
Closed -$4K – 5047
2025
Q4 		$4K Buy
+12,378
New +$6.81K ﹤0.01% 3072

Other funds holding CURX

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
JF
Jump Financial Chicago, Illinois $7.5B AUM 33.9% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

HRT Financial's CURX Position: Q1 2026 in Review

HRT Financial sold out of Curanex Pharmaceuticals (CURX) in Q1 2026, closing a stake of 12,378 shares — an estimated $4K sold.

HRT Financial first reported a position in CURX in Q4 2025 and held it in 1 quarter. The position peaked at $4K in Q4 2025. 8 funds tracked by Wall St. Rank hold CURX as of Q1 2026.

  • HRT Financial reported no remaining Curanex Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • HRT Financial sold 12,378 Curanex Pharmaceuticals shares in Q1 2026, an estimated $4K.
  • HRT Financial first reported a position in Curanex Pharmaceuticals in Q4 2025 and held it in 1 quarter.
  • HRT Financial's Curanex Pharmaceuticals position peaked at $4K in Q4 2025.
  • 8 funds tracked by Wall St. Rank held Curanex Pharmaceuticals as of Q1 2026.

Based on HRT Financial's 13F filing for Q1 2026, filed 14 May 2026.